Healthtech startup Tvaster Genkalp Raises $1.25 Mn From Ideaspring Capital

Molecular diagnostics Platform Tvaster Genkalp has raised $1.25 million in a pre-series A funding round led by Ideaspring Capital.

Existing investors include Invigo Softwares and Prof Mohamed Rela, a liver transplant surgeon, also participated in this round.

The fresh funds will be used to help expand and promote Episcreen Liver, a new blood test that can detect liver cancer early with 90% accuracy. This test is a better alternative to the current method, Alpha-Fetoprotein (AFP), which only has a 50% sensitivity.

Read also- Bajaj Auto Leads In Electric Two-Wheeler Sales In March

“The funding will accelerate nationwide deployment of Episcreen Liver, offering a non-invasive, highly accurate diagnostic alternative for Hepatocellular Carcinoma (HCC), the most common form of liver cancer. Alpha-Fetoprotein (AFP), the current standard for HCC screening, has 50% sensitivity, Episcreen Liver achieves 90% sensitivity thus significantly improving early detection and increasing survival chances by over 70%, said, " Dr. Srikar Raman, Co-Founder and CEO of Tvaster Genkalp.

“We see immense potential in Tvaster’s approach, not just for initial diagnosis but also for monitoring recurrence in patients undergoing treatment. Their liquid biopsy test, Episcreen Liver, has been developed and validated using over 600 patient samples, achieving 90% sensitivity and specificity for detecting hepatocellular carcinoma (HCC). Early detection can significantly improve the survival rates and ensure patients receive curative treatment early on. Ideaspring is very excited to partner with Srikar and Durga scale Tvaster.” Naganand Doraiswany, MD at Ideaspring Capital said.

About Tvaster Genkalp

Founded in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, Tvaster is developing accurate, non-invasive cancer tests using molecular diagnostics and epigenetic screening technologies. 

The company focuses on improving early cancer detection, particularly for liver cancer, which affects over 900,000 people worldwide each year.

Tvaster has tested its Episcreen Liver on more than 600 patients and plans to collaborate with leading diagnostic labs to expand access. 

The company is also working on tests for bile duct cancer and childhood liver cancer treatment resistance.

Tvaster Genkalp recently won the ILTS Young Researcher Award and received a BIRAC BIG Grant for its work in cancer diagnostics.

Startup Funding News: Your Gateway to Every Funding Update.

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges and achieving success.